Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
A UHN study suggests that a novel drug could potentially prevent bone fusion in ankylosing spondylitis (AS), a form of arthritis that affects the spine.
AS is an autoimmune disease characterized by chronic inflammation and damage in the spine joints, which can lead to pain and stiffness in the back. As the disease progresses, AS can cause the bones in spine to fuse, thereby reducing a person's mobility and quality of life.
"Although there are treatments that can lessen symptoms in AS, none of these treatments have been conclusively shown to prevent spine fusion," says Dr.
Robert Inman, a Senior Scientist at UHN's Krembil Research Institute at Toronto Western Hospital.
In the study, a team of researchers led by Dr. Inman characterized NDI-031407, a new drug developed by the company Nimbus Therapeutics. This drug inhibits the activity of TYK2, which is a protein that modulates type III immunity, a branch of the immune system responsible for protecting the body against disease-causing bacteria and fungi.
Dysregulation of type III immunity is believed to underpin AS, and genetic studies suggest that TYK2 is also involved.
The researchers showed that NDI-031407 prevented disease progression, by stopping inflammation and joint damage, in two different experimental models of AS. The drug achieved this by dampening the activity of two types of immune cells, Th17 and gamma delta T cells, both of which are key players in type III immunity and are implicated in AS.
"Our study provides compelling evidence that TYK2 modulates the type III immune response and that targeting TYK2 maybe an effective disease-modifying therapeutic for AS with the potential to not only relieve symptoms but also to prevent bone fusion in the spine," adds Dr. Inman.
The majority of this work was performed by Dr. Eric Gracey, a former PhD student under Dr. Inman's supervision. Dr. Gracey is now completing a postdoctoral fellowship in Gent, Belgium, where he is continuing to examine arthritis and help develop new treatments for it.
This work was supported by the Canadian Institutes of Health Research, Nimbus Therapeutics, the Austrian Science Fund and the Toronto General & Western Hospital Foundation.
Read more about the study